November 16, 2025 a 08:00 am
LLY: Fundamental Ratio Analysis - Eli Lilly and Company
Eli Lilly and Company, a key player in the pharmaceutical industry, offers a diverse range of products addressing various medical needs. The company’s commitment to innovation is evident in its extensive pipeline and strong market presence. However, investors should remain vigilant of competitive pressures and regulatory challenges.
Fundamental Rating
Current fundamental metrics suggest Eli Lilly maintains a solid financial standing with room for improvement.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical ratings reflect the company’s efforts to maintain stability in challenging markets.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-14 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| -- | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Analyst Price Targets
Analyst projections indicate a favorable trend with considerable upside potential based on market conditions.
| High | Low | Median | Consensus |
|---|---|---|---|
| $985 | $700 | $889 | $854.67 |
Analyst Sentiment
The consensus among analysts denotes a strong buy sentiment, implying broad confidence in the company's trajectory.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 31 | |
| Hold | 11 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Eli Lilly presents itself as a formidable contender in the pharmaceutical sector, buoyed by a robust portfolio and innovation-driven growth strategy. Its financial fundamentals point to resilience, though challenges from competitors and regulatory landscapes persist. Strategic investments in R&D underpin potential long-term growth. Investors should weigh the promising analyst sentiment against broader market dynamics before making decisions.